

# Prices paid for antiretroviral drugs by low and middle income countries from January 2004 to June 2006 breakdown in semester

## A summary report from the Global Price Reporting Mechanism on Antiretroviral Drugs, August 2006

The Global Price Reporting Mechanism on Antiretroviral Drugs contains information on real transaction prices of bulk quantities of antiretroviral drugs purchased by HIV/AIDS programmes in developing countries. It complements reports of price quotes from pharmaceutical companies<sup>1,2,3</sup> as well as smaller sets of transaction prices published by others<sup>4,5,6</sup>. The transaction data in the Global Price Reporting Mechanism are provided by the Global Fund to Fight AIDS, TB, and Malaria, the International Dispensary Association, John Snow Inc./Deliver, Management Sciences for Health, Missionpharma, the United Nations' Children's Fund, the WHO Contracting and Procurement Service as well as WHO staff working in different countries, and were compiled by the AIDS Medicines & Diagnostics Service in the Department of HIV/AIDS at the World Health Organization.

This summary report contains information on transactions of 26 commonly-used adult formulations of antiretroviral drugs, recommended by WHO for 1st and 2<sup>nd</sup> line antiretroviral treatment<sup>7</sup> (Tables 1a and 1b & 2a and 2b) carried out in year 2004, 2005, and first semester 2006. Data received up to 30<sup>th</sup> June 2006 were included in this report. Data on less-frequently used formulations of antiretroviral drugs and more detail on the transactions summarized in this report can be found in the Global Price Reporting Mechanism's searchable database, which can be accessed at <http://www.who.int/hiv/amds/price/hdd/>.

In our comparative analysis, we use the median price (half of the transactions having a price lower than the median price and half of the transactions having a price higher than the median price). We also give in brackets the range between the 25<sup>th</sup> and the 75<sup>th</sup> percentiles (the range including the values that are up to 25 percent higher or down to 25 percent lower than the median). The range between the 25<sup>th</sup> and the 75<sup>th</sup> percentiles is called the inter-quartile range.

The median value is correctly used with the inter-quartile range (instead of the mean  $\pm$  standard deviation) to summarize or to report markedly non-normally distributed (asymmetrical) data.

For the interpretation and use of the data shown here it is important to note that:

- 1) All prices are shown in US dollars (US\$) per patient year of a defined daily dose of each drug in adults.
- 2) As taxes, tariffs, and/or terms of trade (INCO terms) were not consistently reported, they were not considered in the analysis. Previous investigations by the US Government Accounting Office<sup>3</sup> and MSH suggest that any variation as a result would be 3-15% over the factory or ex-works (EXW) price<sup>2</sup>.
- 3) All transactions listed with a price of US\$ 0 in the GPRM and thus considered to be ARV donations, were removed from analysis along with their corresponding purchase volumes.
- 4) The report is on international transactions of antiretroviral drugs, not about the price consumers pay for these medicines. The latter are often higher (because of tariffs, taxes, transportation, and make-ups during their distribution) or lower (because of subsidies). More on end-user prices can be found on the WHO medicines website at <http://mednet2.who.int/sourcesprices/>

**Table 1a:** Median price (in US\$ for 1 year's treatment at a defined daily dose (DDD)), of first line antiretroviral drugs bought by **low income countries**

INN	Median Price (25 <sup>th</sup> -75 <sup>th</sup> Quartile range) in US\$					
	DDD Tablets or capsules	1st semester 2004	2nd semester 2004	1st semester 2005	2nd semester 2005	1st semester 2006
Stavudine (d4T) 30 mg	2	49 (49 - 49)	49 (49-51)	49 (44-51)	49 (42-49)	39 (39-39)
Stavudine (d4T) 40 mg	2	55 (55-58)	55 (55-55)	55 (45-55)	52 (43-55)	52 (42-54)
Lamivudine (3TC) 150 mg	2	70 (70-84)	70 (70-70)	70 (65-70)	69 (60-70)	87 (70-87)
d4T/3TC 30/150 mg	2	93 (88-102)	77 (77-87)	81 (81-91)	91 (81-104)	97 (97-97)
d4T/3TC 40/150 mg	2	99 (86-106)	80 (80-91)	87 (87-98)	95 (84-107)	97 (97-97)
d4T/3TC/NVP 30/150/200 mg	2	199 (167-212)	154 (153-163)	154 (146-183)	178 (153-185)	140 (140-140)
d4T/3TC/NVP 40/150/200 mg	2	168 (167-190)	159 (156-168)	159 (157-192)	176 (153-194)	142 (142-142)
ZDV/3TC/NVP 300/150/200 mg	2	411 (411-411)	234 (232-234)	-	156 (155-298)	380 (380-380)
Zidovudine (ZDV) 300 mg	2	183 (139-212)	139 (131-212)	136 (128-212)	155 (132-204)	171 (171-171)
ZDV/3TC 300/150 mg	2	234 (190-241)	241 (239-241)	220 (192-238)	211 (198-238)	166 (166-166)
Nevirapine (NVP) 200 mg	2	104 (79-438)	438 (85-438)	436 (88-456)	80 (69-109)	75 (75-75)
Zidovudine (ZDV) 100 mg	6	263 (219-263)	350 (350-350)	346 (176-351)	203 (165-323)	208 (208-277)
Efavirenz (EFV) 600 mg	1	263 (347-383)	347 (347-348)	347 (347-365)	347 (313-347)	330 (330-330)
Efavirenz (EFV) 50 mg	12	575 (568-583)	509 (507-544)	509 (507-535)	507 (507-552)	691 (691-691)
Efavirenz (EFV) 200 mg	3	507 (507-584)	507 (507-510)	507 (507-531)	507 (482-519)	349 (349-349)
ZDV/3TC/ABC 300/150/300 mg	2	1629 (1629-1629)	1365 (1365-1365)	1241 (1241-1241)	1241 (1241-1297)	-

**Table 1b:** Median price (in US\$ for 1 year's treatment at a defined daily dose (DDD)), of first line antiretroviral drugs bought by **middle income countries**

INN	Median Price (25 <sup>th</sup> -75 <sup>th</sup> Quartile range) in US\$										
	DDD Tablets or capsules	1st semester 2004		2nd semester 2004		1st semester 2005		2nd semester 2005		1st semester 2006	
Stavudine (d4T) 30 mg	2	30	(30-41)	55	(37-96)	44	(37-67)	44	(37-65)	30	(30-57)
Stavudine (d4T) 40 mg	2	44	(39-45)	45	(44-57)	57	(44-59)	44	(44-51)	84	(61-294)
Lamivudine (3TC) 150 mg	2	71	(60-73)	74	(70-80)	81	(70-132)	80	(66-90)	80	(59-103)
d4T/3TC 30/150 mg	2	-	-	86	(86-86)	-	-	-	-	73	(73-73)
d4T/3TC 40/150 mg	2	-	-	92	(92-92)	87	(87-87)	-	-	44	(26-62)
d4T/3TC/NVP 30/150/200 mg	2	-	-	178	(166-189)	209	(205-219)	168	(161-216)	132	(132-132)
d4T/3TC/NVP 40/150/200 mg	2	165	(165-165)	161	(160-161)	219	(212-227)	260	(180-263)	141	(141-141)
ZDV/3TC/NVP 300/150/200 mg	2	303	(303-303)	256	(256-256)	-	-	268	(268-268)	252	(252-252)
Zidovudine (ZDV) 300 mg	2	141	(140-141)	204	(170-217)	161	(153-226)	153	(146-190)	174	(174-174)
ZDV/3TC 300/150 mg	2	208	(168-208)	248	(241-263)	212	(172-256)	241	(219-292)	175	(175-270)
Nevirapine (NVP) 200 mg	2	103	(76-103)	94	(80-132)	95	(80-117)	86	(81-112)	59	(59-280)
Zidovudine (ZDV) 100 mg	6	260	(260-260)	241	(241-394)	372	(329-416)	350	(279-372)	153	(153-214)
Efavirenz (EFV) 600 mg	1	347	(347-422)	361	(347-520)	416	(373-538)	398	(374-767)	299	(278-325)
Efavirenz (EFV) 50 mg	12	575	(575-575)	570	(548-592)	570	(559-587)	570	(541-570)	576	(576-576)
Efavirenz (EFV) 200 mg	3	469	(469-507)	487	(470-539)	548	(504-599)	504	(482-578)	351	(351-384)
ZDV/3TC/ABC 300/150/300 mg	2	1307	(1307-1307)	-	-	-	-	-	-	-	-

**Table 2a:** Median price (in US\$ for 1 year's treatment at a defined daily dose (DDD)), of second line antiretroviral drugs bought by **low income countries**

INN	Median Price (25 <sup>th</sup> -75 <sup>th</sup> Quartile range) in US\$										
	DDD Tablets or capsules	1st semester 2004		2nd semester 2004		1st semester 2005		2nd semester 2005		1st semester 2006	
Abacavir (ABC) 300 mg	2	887	(887-887)	887	(887-887)	887	(887-891)	887	(887-887)	887	(637-887)
Didanosine (ddI) 100 mg	4	311	(311-311)	311	(303-311)	311	(311-328)	311	(311-312)	320	(311-373)
Didanosine (ddI) 200 mg	2	311	(291-311)	311	(311-358)	311	(302-327)	311	(311-313)	311	(311-314)
Didanosine (ddI) 400 mg	1	-	-	252	(221-252)	279	(279-279)	288	(288-288)	288	(288-325)
Indinavir (IDV) 400 mg*	4	409	(398-409)	409	(409-818)	409	(394-409)	409	(409-409)	409	(409-438)
Lopinavir/ritonavir (LPV/r) 133/33 mg	6	507	(507-507)	568	(536-594)	548	(507-701)	501	(500-962)	500	(500-924)
Nelfinavir (NFV) 250 mg	10	1132	(1063-1733)	990	(971-990)	1013	(996-1093)	955	(927-1118)	1013	(927-1105)
Ritonavir (RTV) 100 mg***	2	-	-	372	(90-732)	103	(95-110)	84	(84-87)	138	(84-172)
Saquinavir (SQV) 200 mg*	10	-	-	1028	(988-1069)	1010	(1010-1010)	939	(932-947)	932	(932-976)
Tenofovir (TDF) 300mg	1	-	-	308	(305-313)	-	-	301	(299-303)	208	(208-208)

**Table 2b:** Median price (in US\$ for 1 year's treatment at a defined daily dose (DDD)), of second line antiretroviral drugs bought by **middle income countries**

INN	Median Price (25 <sup>th</sup> -75 <sup>th</sup> Quartile range) in US\$										
	DDD Tablets or capsules	1st semester 2004		2nd semester 2004		1st semester 2005		2nd semester 2005		1st semester 2006	
Abacavir (ABC) 300 mg	2	891	(889-952)	935	(866-936)	962	(905-969)	887	(875-893)	1012	(1012-1012)
Didanosine (ddI) 100 mg	4	580	(263-580)	580	(332-584)	446	(292-1287)	307	(307-609)	513	(484-541)
Didanosine (ddI) 200 mg	2	235	(234-235)	219	(206-288)	238	(176-303)	176	(176-487)	-	-
Didanosine (ddI) 400 mg	1	1811	(1811-1811)	1941	(1151-1942)	1811	(1450-1987)	1488	(1025-2293)	508	(398-751)
Indinavir (IDV) 400 mg*	4	394	(394-478)	438	(409-540)	701	(701-701)	438	(423-664)	555	(482-628)
Lopinavir/ritonavir (LPV/r) 133/33 mg	6	4512	(4510-4953)	3899	(581-4695)	636	(565-4468)	614	(581-4468)	4972	(4249-5475)
Nelfinavir (NFV) 250 mg	10	2159	(1620-3466)	1832	(1473-2239)	1935	(1435-2271)	2113	(1633-2230)	1731	(1018-2117)
Ritonavir (RTV) 100 mg***	2	797	(796-798)	722	(570-1489)	103	(95-311)	511	(91-794)	-	-
Saquinavir (SQV) 200 mg*	10	2379	(2373-2379)	3614	(2902-3621)	2523	(1825-2526)	2570	(1856-3092)	-	-
Tenofovir (TDF) 300mg	1	-	-	279	(252-305)	299	(299-303)	1299	(754-1493)	1186	(1049-1323)







\* Protease to be used boosted with ritonavir





\*\*\* The dose of ritonavir is given for its use as booster of other protease inhibitors

The value of the procurement transactions reported here so far for is US\$ 250,830,162, worth of antiretroviral drug procurement data (including paediatric formulations) included in the database since January 2004. The volume of antiretroviral drugs in the GPRM database represents approximately 40% of the volume of transactions by low and middle income countries.





As can be seen in the tables, for a few first line drugs a higher median price was paid by low income countries than by middle income countries. As this observation would appear counterintuitive, we assessed why this happened and found the following. This can in part be explained by) i) the quantity procured for specific formulation, ii) the number of countries for which the specific formulation was procured, iii) the number of transactions, and iv) the source of procurement (research based pharmaceuticals or Generics, different procurement organizations). See annex 1 for details.





**Comparison of median prices between low and middle income countries for first line treatment**





**Comparison of median prices between low and middle income countries for second line treatment**





As this summary report is intended to provide data on antiretroviral drug pricing to governments, non-governmental organizations, donors, international organizations, academia, and individuals or institutions directly involved or interested in the procurement in resource-poor settings, the quality and quantity of the data presented here is of paramount importance.

In order to guarantee that the result of this analysis reflect actually the reality observed in the procurement of ARV market, we have decided to reduce the frequency with which summary reports will be produced from four (4) to two (2) issues per year in order to collect enough data to make a sound and representative analysis. The next summary report will be available in February 2007 and will incorporate the paediatric formulation for selected formulations.

Any suggestions that could improve this report would be greatly appreciated. Please direct your remarks to Mr Boniface Dongmo Nguimfack at [dongmonguimfackb@who.int](mailto:dongmonguimfackb@who.int).

***Annex 1***

<b>First line treatment Low income countries July - December 2004</b>					
<b>INN</b>	<b>Median</b>	<b>Number of smallest units bought</b>	<b>Total value (US\$)</b>	<b>Number of transactions</b>	<b>Number of countries</b>
Stavudine (d4T) 30 mg	49	6565892	434865	48	13
Stavudine (d4T) 40 mg	55	2603132	198088	40	14
Lamivudine (3TC) 150 mg	70	10269480	986102	48	16
d4T/3TC 30/150 mg	77	747645	82654	7	4
d4T/3TC 40/150 mg	80	202979	23124	5	3
d4T/3TC/NVP 30/150/200 mg	154	12027259	2413058	35	14
d4T/3TC/NVP 40/150/200 mg	159	8505797	1741611	27	12
ZDV/3TC/NVP 300/150/200 mg	234	332880	104935	4	1
Zidovudine (ZDV) 300 mg	139	1503180	296161	30	16
ZDV/3TC 300/150 mg	241	6547940	2076385	48	19
Nevirapine (NVP) 200 mg	438	14708732	6654207	80	22
Zidovudine (ZDV) 100 mg	350	728800	114559	11	6
Efavirenz (EFV) 600 mg	347	3200910	3124425	57	17
Efavirenz (EFV) 50 mg	509	77580	9381	12	6
Efavirenz (EFV) 200 mg	507	1472040	645339	33	11
ZDV/3TC/ABC 300/150/300 mg	1365	21600	40392	1	1

<b>Second line treatment Low income countries July - December 2004</b>					
<b>INN</b>	<b>Median</b>	<b>Number of smallest units bought</b>	<b>Total value (US\$)</b>	<b>Number of transactions</b>	<b>Number of countries</b>
Abacavir (ABC) 300 mg	887	206160	251410	6	5
Didanosine (ddI) 100 mg	311	494940	104796	12	12
Didanosine (ddI) 200 mg	311	420120	188317	8	7
Didanosine (ddI) 400 mg	252	2010	1205	3	1
Indinavir (IDV) 400 mg	609	681810	203397	9	6
Lopinavir/ritonavir (LPV/r) 133/33 mg	568	1594440	608033	16	8
Nelfinavir (NFV) 250 mg	990	9931680	2731704	27	8
Ritonavir (RTV) 100 mg	372	107976	78431	8	6
Saquinavir (SQV) 200 mg	1028	221670	58681	2	2
Tenofovir (TDF) 300mg	308	72930	61613	2	2

First line treatment Low income countries January - June 2004					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Stavudine (d4T) 30 mg	49	1224380	78288	13	9
Stavudine (d4T) 40 mg	55	267680	19683	12	8
Lamivudine (3TC) 150 mg	70	1640220	181768	15	13
d4T/3TC 30/150 mg	93	600744	76102	10	4
d4T/3TC 40/150 mg	99	552360	74123	11	4
d4T/3TC/NVP 30/150/200 mg	199	4250280	1005596	12	5
d4T/3TC/NVP 40/150/200 mg	168	4666320	1086142	15	7
ZDV/3TC/NVP 300/150/200 mg	411	9876	5555	1	1
Zidovudine (ZDV) 300 mg	183	724740	145804	9	7
ZDV/3TC 300/150 mg	234	2143200	624408	23	12
Nevirapine (NVP) 200 mg	104	2745564	697299	26	18
Zidovudine (ZDV) 100 mg	263	19260	1921	3	3
Efavirenz (EFV) 600 mg	347	248190	237208	10	4
Efavirenz (EFV) 50 mg	575	5550	746	2	1
Efavirenz (EFV) 200 mg	507	1468080	708602	15	8
ZDV/3TC/ABC 300/150/300 mg	1629	5880	13119	1	1

Second line treatment Low income countries January - June 2004					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Abacavir (ABC) 300 mg	887	337920	426457	9	6
Didanosine (ddI) 100 mg	311	541260	115018	5	5
Didanosine (ddI) 200 mg	311	52200	20446	3	3
Indinavir (IDV) 400 mg	609	552780	147051	6	5
Lopinavir/ritonavir (LPV/r) 133/33 mg	507	2160	500	1	1
Nelfinavir (NFV) 250 mg	1132	3150820	1001978	11	6

First line treatment Low income countries January - June 2005					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Stavudine (d4T) 30 mg	49	7377343	476228	61	19
Stavudine (d4T) 40 mg	55	8372187	575720	53	18
Lamivudine (3TC) 150 mg	70	28917960	2742091	74	19
d4T/3TC 30/150 mg	81	4209723	489265	22	13
d4T/3TC 40/150 mg	87	2106806	292966	19	11
d4T/3TC/NVP 30/150/200 mg	154	51510679	10386752	50	19
d4T/3TC/NVP 40/150/200 mg	159	17185773	3772224	43	17
Zidovudine (ZDV) 300 mg	136	2174598	532701	32	17
ZDV/3TC 300/150 mg	220	27605704	7904607	105	22
Nevirapine (NVP) 200 mg	436	24608684	7978222	79	27
Zidovudine (ZDV) 100 mg	346	578700	76754	15	6
Efavirenz (EFV) 600 mg	347	9044390	8404702	96	21
Efavirenz (EFV) 50 mg	509	413820	50806	10	5
Efavirenz (EFV) 200 mg	507	6698930	2839821	38	12
ZDV/3TC/ABC 300/150/300 mg	1241	71319	121242	2	2

Second line treatment Low income countries January - June 2005					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Abacavir (ABC) 300 mg	887	511278	574966	26	12
Didanosine (ddI) 100 mg	311	653160	159130	18	18
Didanosine (ddI) 200 mg	311	268177	113066	15	11
Didanosine (ddI) 400 mg	279	360	275	1	1
Indinavir (IDV) 400 mg	609	1430820	408184	15	9
Lopinavir/ritonavir (LPV/r) 133/33 mg	548	978660	318868	9	5
Nelfinavir (NFV) 250 mg	1013	5588640	1924476	19	11
Ritonavir (RTV) 100 mg	103	140280	20434	4	2
Saquinavir (SQV) 200 mg	1010	209790	58016	1	1
Tenofovir (TDF) 300mg	-	28710	24088	1	1

First line treatment Low income countries July -December 2005					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Stavudine (d4T) 30 mg	49	13642620	754992	43	17
Stavudine (d4T) 40 mg	52	11046131	647618	43	17
Lamivudine (3TC) 150 mg	69	26627362	2278790	51	19
d4T/3TC 30/150 mg	91	2674080	353086	33	13
d4T/3TC 40/150 mg	95	986040	127214	23	9
d4T/3TC/NVP 30/150/200 mg	178	19681440	3899063	44	20
d4T/3TC/NVP 40/150/200 mg	176	8554680	1764666	36	16
ZDV/3TC/NVP 300/150/200 mg	156	5847240	1255418	12	4
Zidovudine (ZDV) 300 mg	155	6552960	1651956	31	15
ZDV/3TC 300/150 mg	211	27535860	8057221	91	28
Nevirapine (NVP) 200 mg	80	34434099	9337934	68	26
Zidovudine (ZDV) 100 mg	203	1761700	215162	18	11
Efavirenz (EFV) 600 mg	347	10779600	10351375	65	26
Efavirenz (EFV) 50 mg	507	406470	49011	13	9
Efavirenz (EFV) 200 mg	507	1768500	837512	32	19
ZDV/3TC/ABC 300/150/300 mg	1241	109740	189312	3	3

Second line treatment Low income countries July -December 2005					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Abacavir (ABC) 300 mg	887	956700	1185774	17	9
Didanosine (ddI) 100 mg	311	582960	124667	12	12
Didanosine (ddI) 200 mg	311	359880	126317	13	7
Didanosine (ddI) 400 mg	288	383340	302381	10	6
Indinavir (IDV) 400 mg	609	5178600	1438164	22	11
Lopinavir/ritonavir (LPV/r) 133/33 mg	501	1156281	283748	14	7
Nelfinavir (NFV) 250 mg	955	4788450	1502827	21	13
Ritonavir (RTV) 100 mg	84	214200	27604	6	4
Saquinavir (SQV) 200 mg	939	548640	142144	5	3
Tenofovir (TDF) 300mg	301	764130	627569	5	3

**First line treatment Low income countries January - June 2006**

INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Stavudine (d4T) 30 mg	39	1120860	71116	36	5
Stavudine (d4T) 40 mg	52	586576	42740	11	5
Lamivudine (3TC) 150 mg	87	1679340	154325	32	6
d4T/3TC 30/150 mg	97	5121960	503830	97	8
d4T/3TC 40/150 mg	97	4291380	454113	98	8
d4T/3TC/NVP 30/150/200 mg	140	20834340	3628762	96	7
d4T/3TC/NVP 40/150/200 mg	142	9779580	1711438	100	7
ZDV/3TC/NVP 300/150/200 mg	380	8220	4277	1	1
Zidovudine (ZDV) 300 mg	171	1772460	398282	19	7
ZDV/3TC 300/150 mg	166	15377820	4682742	104	9
Nevirapine (NVP) 200 mg	75	11419380	1258571	115	9
Zidovudine (ZDV) 100 mg	208	367800	56531	19	6
Efavirenz (EFV) 600 mg	330	3749340	3363538	95	8
Efavirenz (EFV) 50 mg	691	94230	12103	31	5
Efavirenz (EFV) 200 mg	349	600300	240288	38	6

**Second line treatment Low income countries January - June 2006**

INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Abacavir (ABC) 300 mg	887	679440	790604	21	10
Didanosine (ddI) 100 mg	320	435180	92846	6	6
Didanosine (ddI) 200 mg	311	145020	61864	11	6
Didanosine (ddI) 400 mg	288	194880	157152	8	6
Indinavir (IDV) 400 mg	609	1358460	387968	13	9
Lopinavir/ritonavir (LPV/r) 133/33 mg	500	1152540	270350	12	5
Nelfinavir (NFV) 250 mg	1013	3153330	879563	20	9
Ritonavir (RTV) 100 mg	138	225120	37425	7	5
Saquinavir (SQV) 200 mg	932	240300	62433	3	2
Tenofovir (TDF) 300mg	208	179850	101915	3	2

<b>First line treatment Middle income countries January - June 2004</b>					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Stavudine (d4T) 30 mg	30	20040	907	11	8
Stavudine (d4T) 40 mg	44	1048420	63868	28	13
Lamivudine (3TC) 150 mg	71	2046780	192628	33	14
d4T/3TC 30/150 mg	-	-	-	-	-
d4T/3TC 40/150 mg	-	-	-	-	-
d4T/3TC/NVP 30/150/200 mg	-	-	-	-	-
d4T/3TC/NVP 40/150/200 mg	165	28800	6480	1	1
ZDV/3TC/NVP 300/150/200 mg	303	3237360	1340205	13	1
Zidovudine (ZDV) 300 mg	141	617040	126286	9	3
ZDV/3TC 300/150 mg	208	2217500	682279	25	14
Nevirapine (NVP) 200 mg	103	2085580	275583	27	11
Zidovudine (ZDV) 100 mg	260	22200	2637	3	1
Efavirenz (EFV) 600 mg	347	69360	131156	13	10
Efavirenz (EFV) 50 mg	575	240	31	1	1
Efavirenz (EFV) 200 mg	469	1362150	608796	17	6
ZDV/3TC/ABC 300/150/300 mg	1307	29040	51884	6	1

<b>Second line treatment Middle income countries January - June 2004</b>					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Abacavir (ABC) 300 mg	891	144360	175459	3	2
Didanosine (ddI) 100 mg	580	556260	221559	12	12
Didanosine (ddI) 200 mg	235	1183800	379347	12	1
Didanosine (ddI) 400 mg	1811	25260	125290	1	1
Indinavir (IDV) 400 mg	592	432600	154017	12	5
Lopinavir/ritonavir (LPV/r) 133/33 mg	4512	1566180	3477047	20	4
Nelfinavir (NFV) 250 mg	2159	8601660	6956341	32	5
Ritonavir (RTV) 100 mg	797	588624	382058	10	4
Saquinavir (SQV) 200 mg	2379	257850	163397	9	3
Tenofovir (TDF) 300mg	-	-	-	-	-

**First line treatment Middle income countries July -December 2004**

INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Stavudine (d4T) 30 mg	90	437952	35590	17	7
Stavudine (d4T) 40 mg	45	1829880	179070	17	11
Lamivudine (3TC) 150 mg	74	2039860	350656	28	11
d4T/3TC 30/150 mg	86	11940	1401	1	1
d4T/3TC 40/150 mg	92	11940	1489	1	1
d4T/3TC/NVP 30/150/200 mg	177.5	75900	19006	2	2
d4T/3TC/NVP 40/150/200 mg	160.5	575940	129219	6	3
ZDV/3TC/NVP 300/150/200 mg	255.5	9420	3297	1	1
Zidovudine (ZDV) 300 mg	204.4	332460	88720	10	7
ZDV/3TC 300/150 mg	248.2	4346400	1425307	37	11
Nevirapine (NVP) 200 mg	94	2240680	506891	36	14
Zidovudine (ZDV) 100 mg	240.9	3882000	404084	16	3
Efavirenz (EFV) 600 mg	360.5	1788960	2005704	22	9
Efavirenz (EFV) 50 mg	570	56610	6778	2	2
Efavirenz (EFV) 200 mg	487	3302190	1470992	19	9
ZDV/3TC/ABC 300/150/300 mg	-	-	-	-	-

**Second line treatment Middle income countries July -December 2004**

INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Abacavir (ABC) 300 mg	935	149880	164506	3	2
Didanosine (ddI) 100 mg	580	979440	382594	10	10
Didanosine (ddI) 200 mg	219	101980	27893	6	5
Didanosine (ddI) 400 mg	1941	117690	631121	6	3
Indinavir (IDV) 400 mg	657	1300140	466346	9	5
Lopinavir/ritonavir (LPV/r) 133/33 mg	3899	356040	514614	15	7
Nelfinavir (NFV) 250 mg	1831.5	1722420	763339	10	5
Ritonavir (RTV) 100 mg	722	13008768	10146403	5	4
Saquinavir (SQV) 200 mg	3614	90360	61442	3	2
Tenofovir (TDF) 300mg	278.6167	271500	167866	3	2

First line treatment Middle income countries January - June 2005					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Stavudine (d4T) 30 mg	44	5205130	354432	39	8
Stavudine (d4T) 40 mg	56.5	5572541	470072	42	9
Lamivudine (3TC) 150 mg	81	8838620	1116393	52	12
d4T/3TC 30/150 mg	-	-	-	-	-
d4T/3TC 40/150 mg	87	72000	8520	1	1
d4T/3TC/NVP 30/150/200 mg	208.5	13045680	6406122	38	3
d4T/3TC/NVP 40/150/200 mg	219	2656020	1168599	15	4
ZDV/3TC/NVP 300/150/200 mg	-	-	-	-	-
Zidovudine (ZDV) 300 mg	160.6	603040	201319	21	9
ZDV/3TC 300/150 mg	211.7	1784840	693131	14	11
Nevirapine (NVP) 200 mg	97	3578550	547205	33	13
Zidovudine (ZDV) 100 mg	372.3	3191800	363724	17	5
Efavirenz (EFV) 600 mg	416	4311881	5477606	33	12
Efavirenz (EFV) 50 mg	570	523170	69123	12	2
Efavirenz (EFV) 200 mg	548	2779500	1568562	25	9
ZDV/3TC/ABC 300/150/300 mg	-	-	-	-	-

Second line treatment Middle income countries January - June 2005					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Abacavir (ABC) 300 mg	962	112810	147483	10	8
Didanosine (ddI) 100 mg	445.5	318660	296639	22	22
Didanosine (ddI) 200 mg	238	632160	205325	4	4
Didanosine (ddI) 400 mg	1811	68436	352998	4	3
Indinavir (IDV) 400 mg	1044	1618070	701304	10	5
Lopinavir/ritonavir (LPV/r) 133/33 mg	636	801303	964312	28	9
Nelfinavir (NFV) 250 mg	1934.5	1432350	814034	14	8
Ritonavir (RTV) 100 mg	103	520792	385651	15	4
Saquinavir (SQV) 200 mg	2523	549240	375682	5	4
Tenofovir (TDF) 300mg	299.3	11761	9689	5	4

First line treatment Middle income countries July - December 2005					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Stavudine (d4T) 30 mg	44	7168676	450718	28	6
Stavudine (d4T) 40 mg	44	6966204	472970	29	7
Lamivudine (3TC) 150 mg	80	14255520	1888508	50	11
d4T/3TC 30/150 mg	-	-	-	-	-
d4T/3TC 40/150 mg	-	-	-	-	-
d4T/3TC/NVP 30/150/200 mg	168	16279620	7392278	14	4
d4T/3TC/NVP 40/150/200 mg	259.5	6086364	2502812	14	4
ZDV/3TC/NVP 300/150/200 mg	267.6667	73320	26884	1	1
Zidovudine (ZDV) 300 mg	153.3	1099940	342542	17	5
ZDV/3TC 300/150 mg	240.9	3368790	1773225	23	10
Nevirapine (NVP) 200 mg	86	3987588	751548	31	10
Zidovudine (ZDV) 100 mg	350.4	1579800	214152	10	6
Efavirenz (EFV) 600 mg	398	4214760	4898209	33	12
Efavirenz (EFV) 50 mg	570	638940	82863	16	3
Efavirenz (EFV) 200 mg	504	3528000	1657572	22	10
ZDV/3TC/ABC 300/150/300 mg	-	-	-	-	-

Second line treatment Middle income countries July - December 2005					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Abacavir (ABC) 300 mg	887	33240	47365	7	5
Didanosine (ddI) 100 mg	307	338460	121997	15	15
Didanosine (ddI) 200 mg	176	312060	75923	5	2
Didanosine (ddI) 400 mg	1487.5	30690	116556	4	4
Indinavir (IDV) 400 mg	650	2070540	791468	11	7
Lopinavir/ritonavir (LPV/r) 133/33 mg	614	757260	971091	19	8
Nelfinavir (NFV) 250 mg	2113	2936790	1715940	10	5
Ritonavir (RTV) 100 mg	511	327204	252033	7	6
Saquinavir (SQV) 200 mg	2570	337500	177503	7	4
Tenofovir (TDF) 300mg	1299.4	41640	58567	7	4

First line treatment Middle income countries January - June 2006					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Stavudine (d4T) 30 mg	30	25260	1653	3	2
Stavudine (d4T) 40 mg	84	209680	23772	3	3
Lamivudine (3TC) 150 mg	91.5	300060	43511	7	5
d4T/3TC 30/150 mg	73	5040	504	1	1
d4T/3TC 40/150 mg	59.54167	11463	808	2	2
d4T/3TC/NVP 30/150/200 mg	132	142800	25823	1	1
d4T/3TC/NVP 40/150/200 mg	141	92520	17748	1	1
ZDV/3TC/NVP 300/150/200 mg	252.4596	293400	101468	1	1
Zidovudine (ZDV) 300 mg	173.8462	9490	2260	1	1
ZDV/3TC 300/150 mg	175.3217	1548570	938440	5	4
Nevirapine (NVP) 200 mg	59	210240	33951	3	2
Zidovudine (ZDV) 100 mg	153.3	593500	40986	4	3
Efavirenz (EFV) 600 mg	298.5	317160	260330	4	4
Efavirenz (EFV) 50 mg	576	3870	508	1	1
Efavirenz (EFV) 200 mg	351	1110780	359813	6	3
ZDV/3TC/ABC 300/150/300 mg	-	-	-	-	-

Second line treatment Middle income countries January - June 2006					
INN	Median	Number of smallest units bought	Total value (US\$)	Number of transactions	Number of countries
Abacavir (ABC) 300 mg	1012	1260	1745	1	1
Didanosine (ddI) 100 mg	512.5	24720	9345	2	2
Didanosine (ddI) 200 mg	-	-	-	-	-
Didanosine (ddI) 400 mg	508	27900	44894	3	3
Indinavir (IDV) 400 mg	826.5	53640	18404	2	2
Lopinavir/ritonavir (LPV/r) 133/33 mg	4971.5	523440	1076006	4	3
Nelfinavir (NFV) 250 mg	1731	2391930	1001384	4	3
Ritonavir (RTV) 100 mg	-	-	-	-	-
Saquinavir (SQV) 200 mg	-	-	-	-	-
Tenofovir (TDF) 300mg	1186.25	12720	33330	0	0

---

<sup>1</sup> "Sources and Prices of Selected Medicines and Diagnostics for People Living with HIV/AIDS",: A Joint UNICEF, UNAIDS, WHO, MSF Project. United Nations Children's Fund, Joint United Nations Programme on HIV/AIDS, World Health Organization, Médecins Sans Frontières. Geneva, Switzerland. June 2005.

<sup>2</sup> Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries (9th edition). Campaign for Access to Essential Medicines. Médecins Sans Frontières. Geneva, Switzerland. July 2006 (revised).

<sup>3</sup> Global HIV/AIDS Epidemic: Selection of Antiretroviral Medications Provided Under US Emergency Plan is Limited. Report to Congressional Requesters. United States Government Accountability Office. January 2005.

<sup>4</sup> Purchase Price Report. The Global Fund to Fight AIDS, TB, and Malaria. Geneva, Switzerland. August 2006.  
[http://www.theglobalfund.org/en/funds\\_raised/price\\_reporting/default.asp](http://www.theglobalfund.org/en/funds_raised/price_reporting/default.asp)

<sup>5</sup> AFRO Essential Medicines Price Indicator. World Health Organization Regional Office for Africa (WHO AFRO). Brazzaville, Republic of Congo. December 2003.

<sup>6</sup> *International Drug Price Indicator Guide*, 2005 edition. *Guide produced in collaboration with the World Health Organization and supported by the Strategies for Enhancing Access to Medicines (SEAM) Program.*

<sup>7</sup> Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach, 2003 Revision. World Health Organization. Geneva, Switzerland. 2004.